menu
    • menu

    Company profile for Valneva

    NEW Drugs in Dev: 18
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19 and chikungunya. Valneva’s portfolio also includes two commercial vaccines for travelers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ValnevaFrance Flag
    Country
    Country
    France
    Address
    Address
    6 rue Alain Bombard, 44800 Saint-Herblain
    Telephone
    Telephone
    +33 2 28 07 37 10
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://valneva.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/valneva/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/valnevase

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ICMD China

    ICMD China

    Not Confirmed

    envelop Contact Supplier

    ICMD China

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Valneva SE Discloses Share And Voting Rights – March 2026
    Valneva SE Discloses Share And Voting Rights – March 2026

    03 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/03/3267946/0/en/Declaration-of-shares-and-voting-rights-of-Valneva-SE-March-2026.html

    GLOBENEWSWIRE
    03 Apr 2026
    Share Share
    Why Valneva CEO Remains Bullish On Pfizer-Partnered Lyme Vaccine
    Why Valneva CEO Remains Bullish On Pfizer-Partnered Lyme Vaccine

    01 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/valneva-ceo-pfizer-partnered-lyme-vaccine-why-phase-3-miss-doesnt-tell-whole-story

    FIERCE BIOTECH
    01 Apr 2026
    Share Share
    Valneva To Join 26th World Vaccine Congress Events
    Valneva To Join 26th World Vaccine Congress Events

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263299/0/en/Valneva-to-Participate-in-Multiple-Events-at-the-26th-World-Vaccine-Congress-in-Washington-DC.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    Pfizer-Valneva Lyme disease shot shows more than 70% efficacy
    Pfizer-Valneva Lyme disease shot shows more than 70% efficacy

    23 Mar 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-valneva-lyme-disease-shot-shows-more-than-70-efficacy-late-stage-trial-2026-03-23/

    REUTERS
    23 Mar 2026
    Share Share
    Valneva Reports Full Year 2025 Audited Financial Results
    Valneva Reports Full Year 2025 Audited Financial Results

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3257885/0/en/Valneva-Reports-Full-Year-2025-Audited-Consolidated-Financial-Results.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Valneva To Release 2025 Financial Results On March 18, 2026
    Valneva To Release 2025 Financial Results On March 18, 2026

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3252127/0/en/Valneva-to-Report-Full-Year-2025-Consolidated-Financial-Results-on-March-18-2026.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search